BIT Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

BIT Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$377K	Buy	+18,000	New	+$405K	0.02%	77
2025 Q3	–	Sell	-2,055	Closed	-$74.7K	–	120
2025 Q2	$74.7K	Sell	2,055 -19,600	-91%	-$707K	﹤0.01%	78
2025 Q1	$784K	Sell	21,655 -8,215	-28%	-$342K	0.07%	64
2024 Q4	$1.26M	Hold	29,870	–	–	0.1%	65
2024 Q3	$1.66M	Sell	29,870 -2,385	-7%	-$121K	0.15%	54
2024 Q2	$1.33M	Sell	32,255 -8,745	-21%	-$373K	0.1%	64
2024 Q1	$1.91M	Buy	41,000 +39,445	+2,537%	+$1.86M	0.14%	67
2023 Q4	$74.4K	Buy	+1,555	New	+$60.3K	0.01%	94

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BIT Capital's RARE Position: Q1 2026 in Review

BIT Capital opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 18,000 shares worth $377K. The stake represents 0.02% of the portfolio and ranks #77 among its holdings. This is a return to the name: BIT Capital previously reported a position in RARE as recently as Q2 2025.

BIT Capital first reported a position in RARE in Q4 2023 and has held it in 8 quarters since. The position peaked at $1.91M in Q1 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

BIT Capital held 18,000 shares of Ultragenyx Pharmaceutical worth $377K as of Q1 2026.
Ultragenyx Pharmaceutical was a new BIT Capital position in Q1 2026.
Ultragenyx Pharmaceutical made up 0.02% of BIT Capital's portfolio in Q1 2026, its #77 holding.
BIT Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and has held it in 8 quarters since.
BIT Capital's Ultragenyx Pharmaceutical position peaked at $1.91M in Q1 2024.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on BIT Capital's 13F filing for Q1 2026, filed 13 May 2026.